Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies

David Merriam, Connie Chen, Gema Méndez-Lagares, Kenneth A. Rogers, Anthony J. Michaels, Jiangli Yan, Paul Casaz, Keith A. Reimann, François Villinger, Dennis Hartigan-O'Connor

Research output: Contribution to journalArticle

Abstract

The HIV reservoir forming at the earliest stages of infection is likely composed of CCR5+ cells, because these cells are the targets of transmissible virus. Restriction of the CCR5+ reservoir, particularly in the gut, may be needed for subsequent cure attempts. Strategies for killing or depleting CCR5+ cells have been described, but none have been tested in vivo in nonhuman primates, and the extent of achievable depletion from tissues is not known. In this study we investigate the efficacy of two novel cytotoxic treatments for targeting and eliminating CCR5+ cells in young rhesus macaques. The first, an immunotoxin consisting of the endogenous CCR5 ligand RANTES fused with Pseudomonas exotoxin (RANTES-PE38), killed CCR5+ lamina propria lymphocytes (LPLs) ex vivo, but had no detectable effect on CCR5+ LPLs in vivo. The second, a primatized bispecific antibody for CCR5 and CD3, depleted all CCR5+ cells from blood and the vast majority of such cells from the colonic mucosa (up to 96% of CD4+CCR5+). Absence of CCR5-expressing cells from blood endured for at least 1 week, while CCR5+ cells in colon were substantially replenished over the same time span. These data open an avenue to investigation of combined early ART treatment and CCR5+ reservoir depletion for cure of HIV-infected infants.

Original languageEnglish (US)
Pages (from-to)S70-S80
JournalAIDS Research and Human Retroviruses
Volume33
Issue numberS1
DOIs
StatePublished - Nov 1 2017

Fingerprint

HIV
Chemokine CCL5
Mucous Membrane
Blood Cells
Lymphocytes
Bispecific Antibodies
Immunotoxins
Exotoxins
Pseudomonas
Macaca mulatta
Primates
Colon
Ligands
Viruses
Therapeutics
Infection

Keywords

  • bispecific antibodies
  • CCR5
  • HIV
  • immunotoxins
  • RANTES-PE38
  • SIV

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Merriam, D., Chen, C., Méndez-Lagares, G., Rogers, K. A., Michaels, A. J., Yan, J., ... Hartigan-O'Connor, D. (2017). Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies. AIDS Research and Human Retroviruses, 33(S1), S70-S80. https://doi.org/10.1089/aid.2017.0159

Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies. / Merriam, David; Chen, Connie; Méndez-Lagares, Gema; Rogers, Kenneth A.; Michaels, Anthony J.; Yan, Jiangli; Casaz, Paul; Reimann, Keith A.; Villinger, François; Hartigan-O'Connor, Dennis.

In: AIDS Research and Human Retroviruses, Vol. 33, No. S1, 01.11.2017, p. S70-S80.

Research output: Contribution to journalArticle

Merriam, D, Chen, C, Méndez-Lagares, G, Rogers, KA, Michaels, AJ, Yan, J, Casaz, P, Reimann, KA, Villinger, F & Hartigan-O'Connor, D 2017, 'Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies', AIDS Research and Human Retroviruses, vol. 33, no. S1, pp. S70-S80. https://doi.org/10.1089/aid.2017.0159
Merriam D, Chen C, Méndez-Lagares G, Rogers KA, Michaels AJ, Yan J et al. Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies. AIDS Research and Human Retroviruses. 2017 Nov 1;33(S1):S70-S80. https://doi.org/10.1089/aid.2017.0159
Merriam, David ; Chen, Connie ; Méndez-Lagares, Gema ; Rogers, Kenneth A. ; Michaels, Anthony J. ; Yan, Jiangli ; Casaz, Paul ; Reimann, Keith A. ; Villinger, François ; Hartigan-O'Connor, Dennis. / Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies. In: AIDS Research and Human Retroviruses. 2017 ; Vol. 33, No. S1. pp. S70-S80.
@article{c7a3c45150c940e691171d410e60d60f,
title = "Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies",
abstract = "The HIV reservoir forming at the earliest stages of infection is likely composed of CCR5+ cells, because these cells are the targets of transmissible virus. Restriction of the CCR5+ reservoir, particularly in the gut, may be needed for subsequent cure attempts. Strategies for killing or depleting CCR5+ cells have been described, but none have been tested in vivo in nonhuman primates, and the extent of achievable depletion from tissues is not known. In this study we investigate the efficacy of two novel cytotoxic treatments for targeting and eliminating CCR5+ cells in young rhesus macaques. The first, an immunotoxin consisting of the endogenous CCR5 ligand RANTES fused with Pseudomonas exotoxin (RANTES-PE38), killed CCR5+ lamina propria lymphocytes (LPLs) ex vivo, but had no detectable effect on CCR5+ LPLs in vivo. The second, a primatized bispecific antibody for CCR5 and CD3, depleted all CCR5+ cells from blood and the vast majority of such cells from the colonic mucosa (up to 96{\%} of CD4+CCR5+). Absence of CCR5-expressing cells from blood endured for at least 1 week, while CCR5+ cells in colon were substantially replenished over the same time span. These data open an avenue to investigation of combined early ART treatment and CCR5+ reservoir depletion for cure of HIV-infected infants.",
keywords = "bispecific antibodies, CCR5, HIV, immunotoxins, RANTES-PE38, SIV",
author = "David Merriam and Connie Chen and Gema M{\'e}ndez-Lagares and Rogers, {Kenneth A.} and Michaels, {Anthony J.} and Jiangli Yan and Paul Casaz and Reimann, {Keith A.} and Fran{\cc}ois Villinger and Dennis Hartigan-O'Connor",
year = "2017",
month = "11",
day = "1",
doi = "10.1089/aid.2017.0159",
language = "English (US)",
volume = "33",
pages = "S70--S80",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "S1",

}

TY - JOUR

T1 - Depletion of Gut-Resident CCR5+ Cells for HIV Cure Strategies

AU - Merriam, David

AU - Chen, Connie

AU - Méndez-Lagares, Gema

AU - Rogers, Kenneth A.

AU - Michaels, Anthony J.

AU - Yan, Jiangli

AU - Casaz, Paul

AU - Reimann, Keith A.

AU - Villinger, François

AU - Hartigan-O'Connor, Dennis

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The HIV reservoir forming at the earliest stages of infection is likely composed of CCR5+ cells, because these cells are the targets of transmissible virus. Restriction of the CCR5+ reservoir, particularly in the gut, may be needed for subsequent cure attempts. Strategies for killing or depleting CCR5+ cells have been described, but none have been tested in vivo in nonhuman primates, and the extent of achievable depletion from tissues is not known. In this study we investigate the efficacy of two novel cytotoxic treatments for targeting and eliminating CCR5+ cells in young rhesus macaques. The first, an immunotoxin consisting of the endogenous CCR5 ligand RANTES fused with Pseudomonas exotoxin (RANTES-PE38), killed CCR5+ lamina propria lymphocytes (LPLs) ex vivo, but had no detectable effect on CCR5+ LPLs in vivo. The second, a primatized bispecific antibody for CCR5 and CD3, depleted all CCR5+ cells from blood and the vast majority of such cells from the colonic mucosa (up to 96% of CD4+CCR5+). Absence of CCR5-expressing cells from blood endured for at least 1 week, while CCR5+ cells in colon were substantially replenished over the same time span. These data open an avenue to investigation of combined early ART treatment and CCR5+ reservoir depletion for cure of HIV-infected infants.

AB - The HIV reservoir forming at the earliest stages of infection is likely composed of CCR5+ cells, because these cells are the targets of transmissible virus. Restriction of the CCR5+ reservoir, particularly in the gut, may be needed for subsequent cure attempts. Strategies for killing or depleting CCR5+ cells have been described, but none have been tested in vivo in nonhuman primates, and the extent of achievable depletion from tissues is not known. In this study we investigate the efficacy of two novel cytotoxic treatments for targeting and eliminating CCR5+ cells in young rhesus macaques. The first, an immunotoxin consisting of the endogenous CCR5 ligand RANTES fused with Pseudomonas exotoxin (RANTES-PE38), killed CCR5+ lamina propria lymphocytes (LPLs) ex vivo, but had no detectable effect on CCR5+ LPLs in vivo. The second, a primatized bispecific antibody for CCR5 and CD3, depleted all CCR5+ cells from blood and the vast majority of such cells from the colonic mucosa (up to 96% of CD4+CCR5+). Absence of CCR5-expressing cells from blood endured for at least 1 week, while CCR5+ cells in colon were substantially replenished over the same time span. These data open an avenue to investigation of combined early ART treatment and CCR5+ reservoir depletion for cure of HIV-infected infants.

KW - bispecific antibodies

KW - CCR5

KW - HIV

KW - immunotoxins

KW - RANTES-PE38

KW - SIV

UR - http://www.scopus.com/inward/record.url?scp=85034255823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034255823&partnerID=8YFLogxK

U2 - 10.1089/aid.2017.0159

DO - 10.1089/aid.2017.0159

M3 - Article

C2 - 28918646

AN - SCOPUS:85034255823

VL - 33

SP - S70-S80

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - S1

ER -